Amplius積極資產配置主動型ETF AAAA 深 滬
已收盤 07-02 16:00:00 美东时间
30.1809
-0.059
-0.20%
華盛通- 最 高30.44
- 今 開30.44
- 成交量 5500股
- 最 低 30.07
- 昨 收 30.24
- 總市值 2.77亿
- 52周最高 30.7225
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 24.4805
- 委 比 0.00%
- 總股本 918.00万
- 歷史最高 30.7225
- 量 比 1.41
- 振 幅 1.22%
- 歷史最低 24.4805
- 每 手 1
- 風險率 1.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多“国联绿色科技”递表港交所，国家级资质认证加持，蒸发冷技术构建核心壁垒
国联绿色科技于2026年5月11日向港交所递交招股书，拟在香港主板上市，联席保荐人为申万宏源香港、国联证券国际。公司是中国领先的全周期智慧能源管理解决方案提供商，2024年收入7.37亿元，净利润0.49亿元，毛利率19.27%；2025年收入6.39亿元，净利润0.5亿元，毛利率22.5%。据弗若斯特沙利文数据，按2025年收入计，公司位列中国第二大全周期智慧能源管理解决方案提供商，且是华东地区最大的全周期智慧能源管理服务商。公司自主研发了一系列高效蒸发冷产品及智慧能碳管理平台，并入选工信部信赖创新解决方案名单。主要股东包括国联发展集团、Johnson Controls、无锡地铁集团等。中介团队共计8家，保荐人2家，整体表现中规中矩。
05-14 17:11
DBV Technologies GAAP EPS of -$0.11
DBV Technologies press release (DBVT): Q1 GAAP EPS of -$0.11. Cash Position and LiquidityOn March 31, 2026, the Company held $229 million in Cash and Cash Equivalents compared to $194 million of Cash ...
05-01 05:09
DBV Technologies GAAP EPS of -$1.05
DBV Technologies press release (DBVT): FY GAAP EPS of -$1.05. On December 31, 2025, DBV held $194.2 million in cash and cash equivalents compared to $32.5 million of cash and cash equivalents on Decem...
03-27 17:16
Upstream Bio Plans To Initiate Dosing In Phase 3 Trials In Both Severe Asthma And CRSwNP In Q1 2027
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP –– Company plans to initiate
03-26 19:19
BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score
BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score March 1 (Reuters) - Upstream Bio Inc UPB.O : UPSTREAM BIO PRESENTS ADDITIONAL ANALYSES FROM THE PHASE 2 VIBRANT TRIAL OF VEREKITUG IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AT 2026 AAAAI ANNUAL MEETING UPSTREAM
03-01 22:47
Ionis Unveils New Phase 3 Data For DAWNZERA In Rare Swelling Disorder
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses
02-27 20:06
Cogent Biosciences posts FY2025 cash and cash equivalents of USD 900.8 million
Cogent Biosciences posts FY2025 cash and cash equivalents of USD 900.8 million Cogent Biosciences Inc. reported cash, cash equivalents, and marketable securities of USD 900.8 million as of December 31, 2025, citing non-recurring fourth quarter cash usage primarily driven by the repayment of USD 54.8
02-17 21:02
The European Commission approves GSK's Exdensur (depemokimab) For Severe Asthma With Type 2 Inflammation And Chronic Rhinosinusitis With Nasal Polyps
GSK plc (LSE/NYSE:GSK) today announced the European Commission has approved Exdensur (depemokimab) in two indications:as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood
02-17 18:20
Cogent Biosciences stellt neue Bezuclastinib-Studienergebnisse bei systemischer Mastozytose vor
Cogent Biosciences stellt neue Bezuclastinib-Studienergebnisse bei systemischer Mastozytose vor Cogent Biosciences Inc. hat angekündigt, dass auf der AAAAI-Jahrestagung 2026 in Philadelphia mehrere Posterpräsentationen mit Ergebnissen der Phase-2-Studie SUMMIT zu Bezuclastinib bei Erwachsenen mit ni
02-10 21:04
Enanta Pharmaceuticals präsentiert präklinische Daten zu KIT-Inhibitor EDP-978 gegen Typ-2-Immunkrankheiten
Enanta Pharmaceuticals präsentiert präklinische Daten zu KIT-Inhibitor EDP-978 gegen Typ-2-Immunkrankheiten Enanta Pharmaceuticals Inc. hat angekündigt, präklinische Daten zu EDP-978, einem KIT-Inhibitor zur Behandlung mastzellvermittelter Typ-2-Immunerkrankungen, auf der Jahrestagung der American A
02-10 20:04
